|
Completed
|
NCT04333732 -
CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
|
Phase 3 |
|
Completed
|
NCT04357457 -
Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia
|
Phase 3 |
|
Terminated
|
NCT04435795 -
Inhaled Ciclesonide for Outpatients With COVID19
|
Phase 2/Phase 3 |
|
Completed
|
NCT04357444 -
Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19
|
Phase 2 |
|
Completed
|
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
|
|
Not yet recruiting
|
NCT05052320 -
Audiological Assessment of Recovered Covid 19 Subjects.
|
|
|
Withdrawn
|
NCT04426344 -
Core Warming of COVID-19 Patients
|
N/A |
|
Recruiting
|
NCT05595031 -
Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
|
|
|
Terminated
|
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 |
|
Terminated
|
NCT04401410 -
Anti-SARS Cov-2 T Cell Infusions for COVID 19
|
Phase 1 |
|
Completed
|
NCT04445337 -
Stellate Ganglion Blockade in COVID-19 Positive Patients
|
N/A |
|
Active, not recruiting
|
NCT04374487 -
Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications
|
Phase 2 |
|
Completed
|
NCT04403243 -
COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19
|
Phase 2 |
|
Completed
|
NCT04375644 -
Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)
|
|
|
Completed
|
NCT04394078 -
Impact of COVID-19 Pandemic on Depression and Quality of Life
|
|
|
Recruiting
|
NCT04407923 -
Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
|
|
|
Completed
|
NCT04426305 -
Community Health Workers Against COVID19
|
N/A |
|
Recruiting
|
NCT04492514 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation
|
Phase 2 |
|
Completed
|
NCT04399980 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
|
Phase 2 |
|
Completed
|
NCT04403828 -
Impact of COVID-19 on Personal Protection Among Dentist in Egypt
|
|